Browsing: Viral > HIV / AIDS
Despite long-term antiretroviral therapy, cerebrospinal HIV reservoirs have been identified in individuals living with the virus and linked with a higher rate of cognitive defects.
A new study using CRISPR-Cas9 and long-acting slow-effective release antiretroviral therapy has reported the elimination of replication-competent HIV-1 DNA from the genomes of living animals for the first time.
In this interview we talk to Jose Arribas about the challenges facing antiretroviral treatments and the future of long-acting formulations for HIV. What new drugs might we have for this disease in the coming years? Read our interview to find out more.
In this interview we speak to David Padley from the National Institute for Biological Standards and Control about his recent poster ‘Point-of-Care testing for HIV: specialist quality control materials are a necessity’, presented at ECCMID 2019.
Take a look at this month’s industry headlines including US FDA approvals for Mavyret (hepatitis C) and Dengvaxia, a rejection for Contepo and profits for Gilead Sciences.
Early antiretroviral treatment in people with HIV infection could allow the generation of more functional and persistent CD8 T cell responses. The results, which suggest a long-term immune memory, could have implications for HIV vaccine development.
Delivering HIV vaccines via slow-release methods has enhanced the protective immune response in preclinical models, according to new research.
Take a look at this month’s industry headlines including news from ViiV Healthcare on long-acting and single dose formulations, sales for Eli Lilly and the possible development of a plague vaccine.